FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a hydrate thereof, a crystalline form of a hydrate or a free form, which is
EFFECT: obtaining a new compound that has the property of an Nrf2 activator and can be used for the treatment of mediated diseases, for example, heart failure with reduced ejection fraction.
10 cl, 15 dwg, 6 tbl, 40 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| 5-SUBSTITUTED INDAZOLE AS KINASE INHIBITORS | 2008 |
|
RU2487873C2 |
| BENZYLAMINE DERIVATIVES | 2014 |
|
RU2660421C2 |
| PYRIDOXAZINONE DERIVATIVES AS TNAP INHIBITORS | 2016 |
|
RU2715704C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES USEFUL AS PLASMA KALLIKREIN INHIBITOR | 2014 |
|
RU2712621C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | 2008 |
|
RU2479584C2 |
| PYRIDINONE PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | 2007 |
|
RU2472782C2 |
| QUINOLINE-2 DERIVATIVES AS C-KIT KINASE INHIBITORS | 2016 |
|
RU2754858C2 |
| TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | 2012 |
|
RU2632870C2 |
